Insider Buying: Fluidigm Corporation (FLDM) Insider Buys 60,000 Shares of Stock

Fluidigm Corporation (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. purchased 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average cost of $5.25 per share, with a total value of $315,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Levin Capital Strategies, L.P. also recently made the following trade(s):

  • On Thursday, August 17th, Levin Capital Strategies, L.P. purchased 465 shares of Fluidigm Corporation stock. The stock was acquired at an average cost of $3.66 per share, with a total value of $1,701.90.
  • On Thursday, August 10th, Levin Capital Strategies, L.P. purchased 4,003,129 shares of Fluidigm Corporation stock. The stock was acquired at an average cost of $3.30 per share, with a total value of $13,210,325.70.
  • On Wednesday, August 9th, Levin Capital Strategies, L.P. purchased 1,549 shares of Fluidigm Corporation stock. The stock was acquired at an average cost of $3.18 per share, with a total value of $4,925.82.

Fluidigm Corporation (NASDAQ FLDM) traded down 3.31% during trading on Thursday, reaching $5.26. The company’s stock had a trading volume of 208,642 shares. The firm’s 50-day moving average price is $4.04 and its 200 day moving average price is $4.62. The company’s market capitalization is $154.72 million. Fluidigm Corporation has a 12-month low of $2.52 and a 12-month high of $8.82.

Fluidigm Corporation (NASDAQ:FLDM) last issued its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $23.50 million. During the same period in the prior year, the business earned ($0.63) EPS. The business’s revenue for the quarter was down 15.2% compared to the same quarter last year. On average, analysts predict that Fluidigm Corporation will post ($2.13) earnings per share for the current fiscal year.

WARNING: “Insider Buying: Fluidigm Corporation (FLDM) Insider Buys 60,000 Shares of Stock” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/14/insider-buying-fluidigm-corporation-fldm-insider-buys-60000-shares-of-stock.html.

Several hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its holdings in shares of Fluidigm Corporation by 4.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,348,419 shares of the medical research company’s stock worth $9,485,000 after buying an additional 89,482 shares during the period. Neuberger Berman Group LLC lifted its holdings in shares of Fluidigm Corporation by 58.1% in the 1st quarter. Neuberger Berman Group LLC now owns 1,924,408 shares of the medical research company’s stock worth $10,950,000 after buying an additional 707,410 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Fluidigm Corporation by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,181,883 shares of the medical research company’s stock worth $6,725,000 after buying an additional 19,669 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Fluidigm Corporation by 2.4% in the 1st quarter. Wellington Management Group LLP now owns 630,277 shares of the medical research company’s stock worth $3,587,000 after buying an additional 14,814 shares during the period. Finally, State Street Corp lifted its holdings in shares of Fluidigm Corporation by 6.2% in the 2nd quarter. State Street Corp now owns 499,524 shares of the medical research company’s stock worth $2,017,000 after buying an additional 29,110 shares during the period. Institutional investors and hedge funds own 88.90% of the company’s stock.

A number of analysts recently commented on the company. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Fluidigm Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply